Compounded Semaglutide: How It Works and What It Treats

For this compounded semaglutide overview, the useful starting point is not whether the internet is excited about it. It is whether the evidence, safety limits, prescription pathway, and follow-up plan are strong enough to support a real patient decision.

A patient I’ll call Laura sat across from me on a telehealth screen last November, holding up two pharmacy printouts. One was a $1,287 cash quote for Wegovy from her Walgreens in suburban Dallas. The other was a screenshot from a compounded telehealth program offering the same molecule for about a fifth of that. “Are these the same thing or not?” she asked. It’s the question I get more than any other, and the honest answer is: sort of. The active ingredient is the same. Almost everything else about the product, the regulatory category, and the supply chain is different. Understanding those differences is the whole game.

The Molecule and Why It Matters That It’s One Molecule

Semaglutide is a GLP-1 receptor agonist. GLP-1 (glucagon-like peptide-1) is an incretin hormone your gut secretes when you eat. It does several things at once: it tells your pancreas to release insulin in a glucose-dependent way, it tells your liver to ease up on glucagon, it slows gastric emptying (which is why you feel full longer), and it acts on hypothalamic appetite centers in the brain. Semaglutide is an engineered analog with a long enough half-life to work as a once-weekly injection.

Novo Nordisk brought it to market as Ozempic in 2017 for type 2 diabetes and as Wegovy in 2021 for chronic weight management. The STEP trial program gave it the weight-loss evidence base. STEP-1 randomized 1,961 adults with overweight or obesity (no diabetes) to semaglutide 2.4 mg weekly or placebo for 68 weeks plus lifestyle counseling. The semaglutide group lost approximately 14.9% of body weight versus 2.4% in the placebo arm (Wilding et al., New England Journal of Medicine, 2021). STEP-5 extended follow-up to 104 weeks and showed sustained weight reduction. On the diabetes side, the SUSTAIN program established glycemic benefit at the lower dose range (0.5 mg and 1.0 mg weekly, with 2.0 mg added in SUSTAIN FORTE), and the cardiovascular outcome trial SUSTAIN-6 (Marso et al.) showed a reduction in major adverse cardiovascular events in high-risk patients.

The boring truth about compounded semaglutide is that the active pharmaceutical ingredient is the same semaglutide. It’s prepared by a state-licensed or 503A compounding pharmacy for an individual patient under a clinician’s prescription, rather than rolling off Novo Nordisk’s manufacturing line as a finished, FDA-approved product. That distinction matters legally, regulatorily, and practically. But the molecule binding to GLP-1 receptors in your gut and your brain doesn’t know which building it was formulated in.

What “Compounded” Actually Means (and Doesn’t)

Compounding is not new or exotic. It predates the modern pharmaceutical industry. Section 503A of the Federal Food, Drug, and Cosmetic Act governs the traditional compounding pathway: a licensed pharmacist prepares a medication for a specific patient based on a valid prescription. Hospitals, dermatology practices, and pain clinics have relied on compounding for decades.

The catch is that compounded preparations are not FDA-approved as finished products. They haven’t gone through the registrational trial process as compounded formulations. The clinical evidence base from STEP and SUSTAIN was built on the brand-name finished product. That evidence informs what we expect from compounded semaglutide, but it does not directly extend to it in the way regulators define “direct extension.” This is an important nuance, not a disqualification. Think of it like this: if you bake a chocolate cake using the same recipe and same ingredients as a professional bakery, the FDA hasn’t inspected your kitchen, but nobody is arguing you made a different cake.

The manufacturing oversight is also different. Brand-name products are manufactured under cGMP at industrial scale with the full apparatus of FDA post-marketing surveillance. Compounding pharmacies are regulated primarily by state boards of pharmacy, with 503B outsourcing facilities subject to additional FDA oversight. Adverse-event reporting is less systematic for compounded preparations.

None of this means compounded semaglutide is dangerous by default. It means the framework for evaluating it is different, and patients benefit from knowing what those differences are rather than having them glossed over.

Titration, Dosing, and the Stuff That Affects Your Tuesday Morning

The standard titration schedule, reflected in the Wegovy label and the STEP trials, is a five-step escalation:

• 0.25 mg weekly for four weeks
• 0.5 mg weekly for four weeks
• 1.0 mg weekly for four weeks
• 1.7 mg weekly for four weeks
• 2.4 mg weekly as maintenance

Full escalation takes about sixteen to seventeen weeks. Most compounded programs follow the same milligram increments, though the concentration of the solution and the volume you draw into the syringe vary by pharmacy. What matters is the milligram dose, not whether you’re injecting 0.25 mL or 0.5 mL of liquid. If you’re switching programs, confirm the milligrams at each step.

The schedule is not sacred. A patient struggling with nausea at 0.5 mg can sit at that dose for an extra four weeks. A patient doing well clinically at 1.7 mg, losing weight, feeling good, tolerating the medication, can stay there instead of pushing to 2.4 mg. This is a clinical decision, not a checkbox exercise.

Day-to-day logistics: store in the refrigerator (36 to 46°F), with brief room-temperature excursions acceptable for transport. Rotate injection sites between abdomen, thigh, and upper arm. Pick a day of the week and try to stick to it.

Side Effects: The First Eight Weeks Are the Worst

Gastrointestinal symptoms dominate. Nausea, diarrhea, constipation, vomiting, abdominal discomfort. The STEP and SUSTAIN programs reported them consistently, and real-world experience confirms it. Most events are mild to moderate and clustered in the first eight to twelve weeks, particularly during dose escalations. They typically resolve with continued use or a temporary dose hold.

Less common but more serious: gallbladder events (especially in patients losing weight rapidly), acute pancreatitis (rare, but stop the medication and get evaluated immediately if you develop severe abdominal pain radiating to the back), and a theoretical thyroid C-cell tumor signal based on rodent studies that has not been replicated in humans. The Wegovy and Ozempic labels carry a boxed warning about the rodent thyroid finding and a contraindication for patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN2).

Hypoglycemia is uncommon on semaglutide alone in non-diabetic patients because insulin release is glucose-dependent. The risk goes up when semaglutide is combined with insulin or sulfonylureas, and the fix is adjusting those medications, not necessarily dropping semaglutide.

One thing I tell patients: the early nausea is real, it is temporary for most people, and it is manageable. Eating smaller meals, avoiding high-fat foods in the first few weeks, and staying hydrated make a meaningful difference. If you’re vomiting for more than 24 hours or can’t keep fluids down, call your prescriber. That’s not a “tough it out” situation.

Cost, Access, and Why the Price Gap Exists

Brand-name Wegovy and Ozempic list above $1,300 per month in the US. Cash-pay rates at most retail pharmacies run $1,000 to $1,400. Insurance coverage for weight management is spotty. The diabetes indication has better coverage but still varies by plan, by employer, by formulary tier.

Compounded semaglutide programs operating within compliant telehealth structures charge substantially less. HealthRX, for example, prices its program at $179.99 to $279.99 per month depending on dose, available in 44 US states and operated under LegitScript certification. The price difference is not a mystery or a red flag. Brand-name products carry the cost of large-scale manufacturing, regulatory submissions, post-marketing surveillance, and the margin Novo Nordisk needs to fund its pipeline. Compounded preparations are produced at a different scale through a different regulatory pathway with a fundamentally different cost structure.

For patients using HSA or FSA accounts, confirm the program’s invoicing format before enrolling. Some programs issue receipts that satisfy the documentation requirements; others don’t.

Patients who want a fuller framing of the clinical and practical questions around compounded semaglutide can read this compounded semaglutide overview, which is organized around the kinds of questions that come up in real intake conversations. It’s background reading, not a replacement for talking to your clinician.

When to Call Someone Instead of Googling

Several situations call for a direct conversation with your prescriber, not a Reddit thread:

• Severe, persistent abdominal pain, especially with back radiation or fever
• Inability to keep fluids down for more than 24 hours, signs of dehydration, persistent vomiting
• New right upper quadrant pain after meals, or jaundice (gallbladder territory)
• New or worsening reflux that doesn’t respond to meal-timing changes
• Mood changes, including new or worsening depressive symptoms
• Pregnancy, planned pregnancy, or breastfeeding (have this conversation before taking the next dose)
• Hypoglycemic episodes if you’re on insulin, sulfonylureas, or other glucose-lowering agents
• If you’re on warfarin or other narrow-therapeutic-window medications and wondering whether slowed gastric emptying might affect absorption

Personal or family history of medullary thyroid carcinoma or MEN2 is an absolute contraindication. If that wasn’t caught at intake, bring it up immediately.

Frequently Asked Questions

Is compounded semaglutide the same drug as Ozempic and Wegovy?

The active ingredient, semaglutide, is the same. The finished product, the regulatory category, and the manufacturing pathway are different. Brand-name Ozempic and Wegovy are FDA-approved finished products manufactured by Novo Nordisk. Compounded semaglutide is prepared by a licensed compounding pharmacy for an individual patient under a clinician’s prescription and is not FDA-approved as a finished product.

How long does treatment typically last?

The STEP-1 trial dataset captures 68 weeks of treatment, STEP-5 extends to 104 weeks, and clinical experience now reaches beyond two years. Treatment duration is individualized based on goals, response, and tolerability.

Is the weight reduction sustained after stopping?

STEP-4 showed significant regain in the group switched to placebo after a lead-in period, suggesting the metabolic effect depends on continued therapy for many patients. Long-term outcomes after discontinuation hinge on the lifestyle changes a patient consolidates during treatment.

Do I need labs to start?

A responsible program will document baseline labs, which may include a metabolic panel, lipid panel, A1c, and in some patients a thyroid panel. The specific set depends on your clinical picture.

Is semaglutide right for everyone?

No. Pregnancy, breastfeeding, personal or family history of medullary thyroid carcinoma or MEN2, and certain GI conditions are contraindications or relative contraindications. A thorough intake conversation surfaces these before therapy begins.

What if I can’t tolerate the nausea?

Stay at the current dose longer, or step back to the previous dose. Most nausea improves within a few weeks at a stable dose. If it doesn’t, your prescriber may slow the titration further or discuss adjunctive strategies.

Can I switch from brand-name to compounded semaglutide (or vice versa)?

Yes, but confirm your milligram dose at the transition. The concentration and injection volume may change. Your prescriber should be involved in the switch.

References: Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine 2021;384:989-1002 (STEP-1). Wadden TA et al. STEP-3. Rubino DM et al. STEP-4. Garvey WT et al. STEP-5. Davies M et al. STEP-2. SUSTAIN-6 (Marso SP et al.). Wegovy and Ozempic prescribing information (Novo Nordisk).

Important Notice

Not FDA-approved. Compounded semaglutide is prepared by licensed compounding pharmacies for individual patients based on a prescriber’s clinical judgment. This article is educational and does not constitute medical advice. Individual results vary.